Skip to main content
TipRanks
Go Ultimate75% OFF

BridgeBio Oncology Therapeutics (BBOT) Stock Statistics & Valuation Metrics

79 Followers

Total Valuation

BridgeBio Oncology Therapeutics has a market cap or net worth of $158.90M. The enterprise value is $137.27M.

Market Cap
$158.90M
Enterprise Value
$137.27M

Share Statistics

BridgeBio Oncology Therapeutics has 80,251,270 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
80,251,270
Owned by Insiders
22.45%
Owned by Institutions
69.98%

Financial Efficiency

BridgeBio Oncology Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.23%.

Return on Equity (ROE)
-0.33
Return on Assets (ROA)
-0.30
Return on Invested Capital (ROIC)
-35.23%
Return on Capital Employed (ROCE)
-0.35
Revenue Per Employee
0
Profits Per Employee
-1.46M
Employee Count
92
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of BridgeBio Oncology Therapeutics is -0.00. BridgeBio Oncology Therapeutics’s PEG ratio is 0.00.

PE Ratio
-0.00
PS Ratio
0.00
PB Ratio
0.54
Price to FCF
-1.05
Price to Operating Cash Flow
-1.05
PEG Ratio
0.00

Income Statement

In the last 12 months, BridgeBio Oncology Therapeutics had revenue of 0 and earned -134.04M in profits. Earnings per share was -4.30.

Revenue
0
Gross Profit
0
Operating Income
-145.82M
Pretax Income
-134.04M
Net Income
-134.04M
EBITDA
-145.21M
Earnings Per Share (EPS)
-4.30

Cash Flow

In the last 12 months, operating cash flow was -150.88M and capital expenditures -157,000, giving a free cash flow of -151.03M billion.

Operating Cash Flow
-150.88M
Free Cash Flow
-151.03M
Free Cash Flow per Share
-1.88

Dividends & Yields

BridgeBio Oncology Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-96.27%
Earnings Yield
-109.42%

Stock Price Statistics

Beta
0.69
52-Week Price Change
-85.87%
50-Day Moving Average
3.65
200-Day Moving Average
7.59
Relative Strength Index (RSI)
30.24
Average Volume (3m)
623.11K

Important Dates

BridgeBio Oncology Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

BridgeBio Oncology Therapeutics as a current ratio of 12.14, with Debt / Equity ratio of 0.67%

Current Ratio
12.14
Quick Ratio
12.14
Debt to Market Cap
0.01
Net Debt to EBITDA
2.55
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, BridgeBio Oncology Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

BridgeBio Oncology Therapeutics EV to EBITDA ratio is -0.46, with an EV/FCF ratio of -0.55.

EV to Sales
0.00
EV to EBITDA
-0.46
EV to Free Cash Flow
-0.55
EV to Operating Cash Flow
-0.55

Balance Sheet

BridgeBio Oncology Therapeutics has $193.87M in cash and marketable securities with $2.38M in debt, giving a net cash position of $191.49M billion.

Cash & Marketable Securities
$193.87M
Total Debt
$2.38M
Net Cash
$191.49M
Net Cash Per Share
$2.39
Tangible Book Value Per Share
$3.66

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for BridgeBio Oncology Therapeutics is $18.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$18.88
Price Target Upside
872.94% Upside
Analyst Consensus
Strong Buy
Analyst Count
9
Revenue Growth Forecast
―
EPS Growth Forecast
-132725.78%

Scores

Smart Score
6
AI Score
43